|
🏷️ 产品编码
RB9T37014895
|
🧬 中文名称
抗人Siglec-3/CD33参考抗体
|
|
📝 英文名称
Anti-Human Siglec-3/CD33 Reference Antibody
| |
|
📦 形态
Liquid
|
🧪 纯度
>95% purity as determined by SDS-PAGE.
|
|
🔹 内毒素水平
Please contact the lab for this information.
| |
|
🔬 应用
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
| |
|
🧫 表达系统
Mammalian Cells
|
🔢 登录号
P20138
|
|
🔹 宿主种属
Humanized
|
🔹 克隆性
Monoclonal
|
|
🔹 抗体亚型
IgG1-kappa
|
🔹 纯化方式
Protein A/G purified from cell culture supernatant.
|
|
🔹 浓度
1.39mg/ml
|
🔹 种属反应性
Human
|
|
🔹 靶标
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
|
🔹 背景信息
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin . Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. |
|
🏷️ 别名
225Ac-lintuzumab, HuM195, SGN-33, SMARTM195, HuM195, 166089-32-3
| |
|
🔹 产品描述
Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225Ac]Ac-lintuzumab clinical trials were discussed in detail in reference. Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
| |